BXP Q1 2023 FFO $1.73/share, revenue up 6.5%; commences two life sciences projects in Cambridge

BXP, Inc.

2023-Q1 EPS reported $0.50 revenue$803,200,000

Q1 revenue $803.2M (+6.5% YoY); net income $77.9M ($0.50 EPS) vs $143.0M ($0.91 EPS) in Q1 2022.
FFO $272.0M ($1.73/share) vs $286.1M ($1.82/share) in Q1 2022; FFO beat guidance mid-point by $0.06.
Commenced development of 290 Binney St (566k sq ft lab, 100% pre-leased to AstraZeneca for 15 years) and redevelopment of 300 Binney St (236k sq ft lab, pre-leased to Broad Institute for 15 years).
Closed $1.2B term loan facility in Jan 2023; used $730M to repay maturing term loan, net proceeds ~$464M.
Guidance: Q2 2023 EPS $0.59-$0.61, FFO $1.79-$1.81; FY 2023 EPS $2.30-$2.36, FFO $7.14-$7.20.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BXP, Inc. reported first quarter ended March 31, 2023 results: revenue $803.2 million, net income $77.9 million, EPS $0.50 per diluted share (EPS).

Period: first quarter ended March 31, 2023
Revenue: $803.2 million
Net income: $77.9 million
EPS: $0.50 per diluted share (EPS)
Result: reported results

Exact text from the filing

Financial highlights for the first quarter include: • Revenue increased 6.5% to $803.2 million for the quarter ended March 31, 2023, as compared to $754.3 million for the quarter ended March 31, 2022. • Net income attributable to common shareholders of $77.9 million, or $0.50 per diluted share (EPS), for the quarter ended March 31, 2023

View on SEC.gov

4 earnings releases filed in the last 30 days. Browse all earnings releases →

BXP, Inc. filing history →

Source: SEC EDGAR

accession 0001656423-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.